Skip to main content
    P

    Prime Medicine, Inc. Common Stock (PRME)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $3.84
    -0.35 (-8.35%)

    Market Cap: $932.06M

    Last updated: Nov 17, 2026 at 4:31 PM ET

    Prime Medicine, Inc. Common Stock (PRME) Valuation Multiples

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    Prime Medicine, Inc. Common Stock (PRME) trades at 96.7x sales and 80.9x book value. Its P/S ranged from 33.6x in 2023 to 346.7x in 2022 across the 4 year ends with a P/S figure.

    Current Multiples

    MultipleValue
    P/E (trailing)N/A
    Forward P/EN/A
    Price to sales96.7x
    Price to book80.9x
    PEGN/A
    FCF yield-23.2%
    As of Nov 17, 2026

    Valuation History

    Over the 4 year ends shown, its P/B ranged from 2.3x in 2024 to 6.5x in 2023.

    Year endPriceP/SP/B
    2025$3.47105.1x4.3x
    2024$2.92113.1x2.3x
    2023$8.8633.6x6.5x
    2022$18.58346.7x5.7x
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported.

    Frequently Asked Questions About PRME

    What is PRME's price to sales ratio?

    Prime Medicine, Inc. Common Stock has a price to sales ratio of 96.7x.